Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With Bsa 5–15% and PGA ≥3: Post-Hoc Analysis From Three Randomized Controlled Trials

<p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p>